An expanding range of targets for kynurenine metabolites of tryptophan
Stone, Trevor W.; Stoy, Nicholas; Darlington, L. Gail;
The kynurenine pathway of tryptophan metabolism accounts for most of the tryptophan that is not committed to protein synthesis and includes compounds active in the nervous and immune systems. Kynurenine acts on the aryl hydrocarbon receptor, affecting the metabolism of ... View more
25. Guidetti, P., Luthi-Carter, R.E., Augood, S.J. and Schwarcz, R. (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461.
26. Guidetti, P., Bates, G.P., Graham, R.K., Hayden, M.R., Leavitt, B.R., MacDonald, M.E., Slow, E.J., Wheeler, V.C., Woodman, B. and Schwarcz, R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 23, 190-197.
27. Forrest, C.M., Mackay, G.M., Stoy, N., Spiden,S.L., Taylor, R., Stone, T.W. and Darlington, L.G. (2010) Blood levels of kynurenines, interleukin-23 and soluble human leukocyte antigen-G at different stages of Huntington's disease. J. Neurochem. 112, 112-122.
28. Wolkin, A., Sanfilipo, M., Wolf, A.P., Angrist, B., Brodie, J.D. and Rotrosen, J. (1992) Negative symptoms and hypofrontality in chronic-schizophrenia. Arch. Gen. Psychiat. 49, 959-965.
30. Morris, B.J., Cochran, S.M. and Pratt, J.A. (2005) PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101-106.
31. Cochran, S.M., Kennedy, M., Mckerchar, C.E., Steward, L.J., Pratt, J.A. and Morris, B.J. (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: Differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275.
32. Erhardt, S., Blennow, K., Nordin, C., Skogh, E. Lindstrom, L.H. and Engberg, G. (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313, 96-98.